Applications of biopolymer scaffolds for intestinal delivery of drug-loaded nano-biomaterials: a review
Abstract Targeting drug delivery in the intestine is still one of the biggest hurdles in pharmaceutical research because of reasons like low bioavailability, enzymatic degradation, rapid transit time, and absorption plight of conventional oral drugs. Intestinal scaffolds are now a new promising plat...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-07-01
|
| Series: | Discover Materials |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s43939-025-00321-8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Abstract Targeting drug delivery in the intestine is still one of the biggest hurdles in pharmaceutical research because of reasons like low bioavailability, enzymatic degradation, rapid transit time, and absorption plight of conventional oral drugs. Intestinal scaffolds are now a new promising platform for localized, controlled, and sustained drug delivery. Scaffolds mimic the physiological environment of the intestine and are made from biodegradable polymers, hydrogel, and any nanomaterial-based composites. They allow very precise spatial and time-controlled drug release while improving mucosal adhesion and interaction with the epithelium. Current advances include bioengineered scaffolds, microfabrication, and smart responsive systems to increase and expand current use in gastrointestinal diseases such as inflammatory bowel disease, colorectal cancer, and malabsorption disorders. Functional modification has produced scaffolds that are pH-sensitive, enzyme-responsive, and microbiota-targeted scaffolds, which can enable personalized, disease-specific therapeutics. Further enhancement of scaffold stability, drug-loading capacity, and site-specific release mechanisms is achieved by adding nanoparticles, bioadhesive polymers, and bioactive molecules. We have carried out this review from an overview perspective on the latest developments in material design, fabrication techniques, or drug release strategies for the next-generation intestinal scaffolds. The focus now has shifted to comparing the advantages of these innovations over conventional oral drug delivery systems and discussing the accompanying risks of biocompatibility, scalability, regulatory approval, and clinical translation, future research directions to ultimately optimize scaffold-based drug delivery. Thus, from precision medicine and regenerative approaches, intestinal scaffolding may change oral drug administration, improving therapeutic outcomes in patients with gastrointestinal disorders while minimizing systemic side effects. |
|---|---|
| ISSN: | 2730-7727 |